Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 12, 2009, Pages 4810-4819

  Hollander, Priscilla ^a   Li, Jia ^b   Allen, Elsie ^b   Chen, Roland ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN;

ADD ON THERAPY; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; DIET RESTRICTION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOOT EDEMA; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT DEPARTMENT; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STEVENS JOHNSON SYNDROME; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 73149084956     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0550     Document Type: Article

References (38)

1. Turner RC, Cull CA, Frighi V, Holman RR 1999 Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012
2. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinamn B, Viberti G; ADOPT Study Group 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443
3. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB 2008 Is glycemic control improving in U.S. adults? Diabetes Care 31:81-86
4. Kimmel B, Inzucchi SE 2005 Oral agents for type 2 diabetes: an update. Clin Diabetes 23:64-76
5. Bailey CJ, Del Prato S, Eddy D, Zinman B 2005 Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. Int J Clin Pract 59:1309-1316
6. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P 2006 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28:1556-1568
7. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S 2007 Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 9:166-174
8. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force 2007 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 13(Suppl 1):1-68
9. Drucker DJ, Nauck MA 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705
10. Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153-165
11. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA 2003 Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52:741-750
12. Barnett A 2006 DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60:1454-1470
13. Amori RE, Lau J, Pittas AG 2007 Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298:194-206
14. Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG 2005 Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:5025-5037
15. Rosenstock J, Sankoh S, List JF 2008 Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 10:376-386
16. Nissen SE, Wolski K 2007 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.NEngl J Med 356:2457-2471
17. American Diabetes Association 2007 Standards of medical care in diabetes. Diabetes Care 30:S4-S41
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
19. Phillips DI, Clark PM, Hales CN, Osmond C 1994 Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11:286-292
20. Matsuda M, DeFronzo RA 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462-1470
21. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ 2001 A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24:539-548
22. Rosner B 2000 Fundamentals of biostatistics. 5th ed. Pacific Grove, CA: Duxbury Press; 511-576
23. Shun Z, Silverberg A, Chang CK, Ouyang P 2003 Dunnett's many-to-one test and least square means. J Biopharm Stat 13:17-28
24. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ 2008 Translating the A1C assay into estimated average glucose values. Diabetes Care 31:1473-1478
25. Ahrén B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE 2009 Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 94:1236-1243
26. McGill JB 2009 Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Postgrad Med 121:46-58
27. Berlie HD, Kalus JS, Jaber LA 2007 Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 76:279-289
28. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R 2004 Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27:256-263
29. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes 2009 Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203
30. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group 2005 Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653; author reply 1751-1752
31. The ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F 2008 Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572
32. Stratton IM, Adler AI, NeilHA,Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR 2000 Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412
33. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA 2008 10-year follow-up of intensive glucose control in type 2 diabetes. UKPDS 80. N Engl J Med 359:1577-1589
34. The Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm Jr RH, Probstfield JL, Simons-Morton DG, Friedewald WT 2008 Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559
35. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators 2009 Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139
36. Dluhy RG, McMahon GT 2008 Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358:2630-2633
37. Jellinger PS, Davidson JA, Blonde L, Einhorn D, Grunberger G, Handelsman Y, Hellman R, Lebovitz H, Levy P, Roberts VL; ACE/AACE Diabetes Road Map Task Force 2007 Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract 13:260-268
38. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J 2001 A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 24:1226-1232